Analysts Set DaVita Inc. (NYSE:DVA) Target Price at $155.80

DaVita Inc. (NYSE:DVA) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $155.80.

A number of equities research analysts have commented on the stock. TD Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Truist Financial set a $158.00 price objective on shares of DaVita in a research report on Thursday, February 5th. UBS Group upped their target price on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Barclays increased their price target on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th.

Institutional Investors Weigh In On DaVita

A number of institutional investors have recently added to or reduced their stakes in DVA. Hantz Financial Services Inc. lifted its holdings in shares of DaVita by 48.1% in the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after buying an additional 75 shares in the last quarter. Elevation Wealth Partners LLC lifted its stake in DaVita by 147.3% in the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after purchasing an additional 165 shares in the last quarter. Caitlin John LLC bought a new position in shares of DaVita during the 4th quarter valued at about $34,000. Canada Pension Plan Investment Board purchased a new position in shares of DaVita during the second quarter valued at about $43,000. Finally, Sankala Group LLC bought a new stake in shares of DaVita in the fourth quarter worth about $39,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

NYSE:DVA opened at $154.73 on Monday. DaVita has a one year low of $101.00 and a one year high of $159.42. The business has a fifty day moving average price of $126.48 and a 200-day moving average price of $126.36. The firm has a market capitalization of $10.34 billion, a price-to-earnings ratio of 15.61, a price-to-earnings-growth ratio of 0.53 and a beta of 0.94.

DaVita (NYSE:DVA) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.62 billion during the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the previous year, the company posted $2.24 earnings per share. DaVita’s revenue for the quarter was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities research analysts expect that DaVita will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.